Delicate prolour valsartan ferrine flat film is approved for high-end imitation drug strategy show new
On March 11th, the Food and Drug Administration official website updated the drug approved information, and the four types of vals and sanguin (I) of Chengdu Dharma Pharmaceutical industry were approved. Listed new products.
Valsamanine is the original product of Nova. Novarta’s valsum tannilleo was approved in the domestic market in 2009, followed by a decade in the Chinese market. Minet data showed that the variety sold in 2017 and sales have increased after the sales of medical insurance catalogs. In the same year, the terminal sales of urban public hospitals, county-level public hospitals, urban community and township health institutions (referred to as China public medical institutions) have broken 10 100 million yuan, rose to 1.6 billion yuan in 2019, the original research product 2017-2019 sales growth rate of sales in China’s urban physical pharmacy terminals exceeded 20%, and the market potential is very amazing. The high-end imitation drug was approved and once again highlights the strong research and development strength of Double Pharmaceutical industry. It is understood that Double Pharmaceuticals was established in 1995, mainly engaged in the research and development, production and sales of high-end imitation drugs, innovative drugs, and raw materials, and is a high-tech enterprise with innovative driving. The company is guided by clinical medical needs, and continuously enriched product line. At present, products cover anti-infective medication, reproductive system medication, cardiovascular system, blood and hematopoietic system, respiratory inhalation administration, etc., have more than 210 The registered volume of 60 raw drugs products, and more than 140 pieces of sales during the reporting period.
At present, the company has a number of domestic first imitation or exclusive products, and 16 product lines are consistently evaluated. Multiple major products such as Male Acid nlons injection, fumarate Novoli dipiofuride tablets, deacetyl The hairolin injection, etc. is included in the various relevant fields of authoritative drug medication in China and abroad, with its competitive advantages such as outstanding efficacy, safe and reliable, quality and stability, in the segmentation area. In order to ensure the cost of the drug from the source, the supply is stable, the company adheres to the layout of the raw materials + preparation, and the main products are mostly autonomous. The company has six major production bases in Chengdu, Haikou, Guang’an, etc., including 4 preparation bases and 2 raw materials production bases. With deep research and development strength, the company undertakes the major new drug creative scientific and technological major projects under the Ministry of Science and Technology, and the provincial major scientific and technological achievements transformation demonstration projects. In 2019, the company was identified by the provincial departments as a postdoctoral innovation practice base in Sichuan Province.
In 2020, the company was assessed as the Chengdu Refractory Drug Engineering Technology Research Center with a systematic difficult drug-soluble drug-related technology platform.
Disclaimer: The market is risky, choose cautious! This article is for reference only, not for trading basis. Editor in charge: kJ005.